Penumbra STORM-PE Trial Shows New Therapy Significantly Improves Function in PE Patients

Penumbra announced 90-day results of the landmark STORM-PE randomized controlled trial, which found that patients with acute intermediate-high risk pulmonary embolism who were treated with computer assisted vacuum thrombectomy plus anticoagulation achieved greater functional improvement, including walking significantly further and a higher proportion of patients achieving NYHA Class I (no physical limitations), compared to anticoagulation alone. The first-of-its kind data were presented at this week's Society of Interventional Radiology Annual Scientific Meeting. At 90 days, patients treated with CAVT plus anticoagulation: Walked significantly longer distances during the six-minute walk test. Near normalized, walking 94% of their predicted walk distance vs 75.2% in the anticoagulation only arm. Experienced no physical limitation based on New York Heart Association Functional Class Scale compared to the anticoagulation only arm. Returned to pre-PE functional status distribution while the anticoagulation only arm did not. Improved quality of life and reduced shortness of breath, which were comparable in both arms. Additionally, safety rates through 90 days were comparable in both arms, with no device-related mortality, no additional PE-related mortality past 7 days, and no difference in symptomatic PE-recurrence, confirming the safety profile of CAVT.